Fig. 6

Selinexor attenuates locomotion defect and reduced mitochondria caused by SARS-CoV-2 Orf6 transgene expression in flies. Comparative assays of phenotypes in wild type (w¹¹¹⁸) and SARS-CoV-2 Orf6 transgenic [overexpression (OE) driven by ubiquitous enhancer Tubulin (Tub)] flies following treatment with Selinexor (0.2 μM). a Quantification of climbing ability. N = 30 flies per group. b Quantification of flies with “held-up” wing phenotype (i.e. % Wing Defect). Four replicates, each replicate N = 50 flies per group. c Representative images of indirect flight muscle (labeled with Phalloidin, red) and mitochondria (labeled with ATP5A, green) morphology. d Quantification of the number of mitochondria in the fly indirect flight muscle, normalized based on wild type (w¹¹¹⁸) counts. N = 10 flies per group. Results are presented as mean ± SD. Statistical significance (*) is defined as P < 0.05